AlphaMark Advisors LLC Has $393,000 Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

AlphaMark Advisors LLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 556.5% in the 3rd quarter, Holdings Channel reports. The firm owned 3,578 shares of the medical equipment provider’s stock after buying an additional 3,033 shares during the quarter. AlphaMark Advisors LLC’s holdings in Lantheus were worth $393,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares in the last quarter. Fidelis Capital Partners LLC bought a new stake in shares of Lantheus during the 1st quarter worth $34,000. FinTrust Capital Advisors LLC grew its stake in Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 232 shares during the last quarter. Nkcfo LLC bought a new position in Lantheus in the 2nd quarter worth $47,000. Finally, UMB Bank n.a. lifted its position in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on LNTH shares. Leerink Partners boosted their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. JMP Securities cut their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research report on Thursday, August 1st. Finally, Truist Financial decreased their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $126.00.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $115.65 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The business’s fifty day moving average price is $105.04 and its two-hundred day moving average price is $90.35. The stock has a market capitalization of $8.02 billion, a price-to-earnings ratio of 17.66 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business’s revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.40 EPS. As a group, analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the transaction, the director now directly owns 454,923 shares in the company, valued at approximately $43,445,146.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Mary Anne Heino sold 10,481 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the transaction, the director now owns 454,923 shares in the company, valued at $43,445,146.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,981 shares of company stock worth $2,689,156. 1.50% of the stock is owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.